Spotlight Medical Secures €6.2M in Seed Funding to Enhance Cancer Treatment Strategies with AI-Powered Prognosis Tests
Summary
PARIS, July 12, 2024--(BUSINESS WIRE)--Spotlight Medical, a pioneering startup developing AI-driven prognosis tests to assist physicians in selecting the most effective treatment for cancer patients, today announced that it has raised 6.2 million in a seed funding round. The investment was led by Kurma Partners and Heal Capital.This funding will enable Spotlight Medical to bring its first prognosis test to the clinic, marking a significant milestone in the commercialization of AI-based solutions for cancer treatment. Christian Lautner from Heal Capital added, "We are convinced the Spotlight Medical team is perfectly positioned to bring an AI-empowered precision oncology platform to clinical practice and thereby have a lasting impact on patients lives. "This investment will accelerate our mission to harness the power of AI in analyzing patient data, providing physicians with the insights they need to make more informed treatment decisions. "Founded in 2024 and backed by world-renowned cancer centers Institut Curie and Gustave Roussy, Spotlight Medical is dedicated to developing clinical tests that exploit the vast amount of information contained in patient data.